MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Vaxcyte Inc

Avatud

SektorTervishoid

33.34 1.09

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.69

Max

34.42

Põhinäitajad

By Trading Economics

Sissetulek

-34M

-137M

Aktsiakasum

-1.018

Töötajad

414

EBITDA

87M

-53M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+274.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-6.3B

3.9B

Eelmine avamishind

32.25

Eelmine sulgemishind

33.34

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Vaxcyte Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2025, 14:19 UTC

Suurimad hinnamuutused turgudel

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3. sept 2024, 17:22 UTC

Peamised uudised

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Võrdlus sarnastega

Hinnamuutus

Vaxcyte Inc Prognoos

Hinnasiht

By TipRanks

274.34% tõus

12 kuu keskmine prognoos

Keskmine 124.13 USD  274.34%

Kõrge 160 USD

Madal 65 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Vaxcyte Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

11

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

30.39 / N/AToetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.